PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|May 15, 2020
- Pharmaceutical Technology-05-15-2020
- Volume 2020 eBook
- Issue 2
Considerations in Contamination Control
Author(s)Susan Haigney
A contamination control strategy can prevent contamination in sterile product manufacturing. The right system, equipment, and personnel training are also essential to mitigate risk.
Advertisement
Pharmaceutical Technology spoke with Richard Denk, senior consultant aseptic processing and containment, SKAN AG, about the risks of contamination in biopharmaceutical manufacturing and how this risk can be mitigated.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2020
May 2020
Pages: 38–42
Citation
When referring to this article, please cite it as S. Haigney, “Considerations in Contamination Control," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).
Articles in this issue
over 6 years ago
On Point: Biologics Drive Growth in Pre-Filled Syringesover 6 years ago
Instrumenting Single-Use Processesover 6 years ago
Best systems and equipment for contamination controlover 6 years ago
Building Data Quality In Generates Quality Data Outover 6 years ago
Detecting Contamination in Cell Therapiesover 6 years ago
Optimizing Viral Vector Manufacturing for Gene Therapyover 6 years ago
Minimizing Contamination During Biopharma R&Dover 6 years ago
Complications in Process Simulation ExecutionAdvertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
The EU is focused on strengthening supply-chain resilience, avoiding medicine shortages, simplifying regulations, and implementing new approach methodologies.
Advertisement
Advertisement